Welcome to our dedicated page for Catalent news (Ticker: CTLT), a resource for investors and traders seeking the latest updates and insights on Catalent stock.
Catalent, Inc. (historically NYSE: CTLT) generates frequent news as a global contract development and manufacturing organization (CDMO) serving pharma, biotech, and consumer health customers. Company announcements emphasize its mission to develop, manufacture, and supply products that help people live better and healthier lives, as well as its role in optimizing product development, launch, and full life-cycle supply.
News about Catalent often covers its corporate transactions and ownership structure. A major recent theme has been the acquisition of Catalent by Novo Holdings A/S, a global life sciences investment firm. Press releases detail the signing of the merger agreement, regulatory approvals, fulfillment of closing conditions, and the completion of the all-cash transaction, after which Catalent became a private company and its common stock ceased trading on the New York Stock Exchange.
Operational updates are another key news category. Catalent has reported expansions of its global network, such as the completion of a significant expansion at its Schorndorf, Germany clinical supply facility, adding temperature-controlled storage, a new automatic bottle filling line, and dedicated space for its FastChain demand-led supply service. The company has also announced portfolio changes, including an agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, New Jersey, which also houses its corporate headquarters during a transition period.
Financial results and segment performance feature prominently in Catalent’s news flow. The company publishes quarterly and annual results, including net revenue, segment performance for Biologics and Pharma and Consumer Health, and non-GAAP metrics such as Adjusted EBITDA and Adjusted Net Income, along with commentary on trends in non-COVID revenue and leverage ratios.
Governance and leadership developments also appear in Catalent’s news, such as new Board appointments and updates to its Board composition under Novo Holdings’ ownership. For readers tracking CTLT-related developments, this news stream provides context on Catalent’s evolution from a public CDMO to a privately held company, its investment in global capacity, and its ongoing role in supporting the development and supply of treatments worldwide.
Catalent, a global leader in drug development and supply, announced the approval of its acquisition by Novo Holdings. At a Special Meeting, Catalent stockholders voted in favor of the Merger with 99.2% approval. Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. Catalent's President and CEO, Alessandro Maselli, expressed gratitude for the stockholders' support and confidence in Catalent's future. The transaction, anticipated to close by the end of 2024, is subject to regulatory approvals and customary closing conditions. The transaction is not contingent on financing.
Catalent, Inc. reported third quarter fiscal 2024 results with a net revenue increase of 4% compared to Q3'23, excluding COVID-related revenue. The net loss decreased from $(227) million in Q3'23 to $(101) million in Q3'24. Adjusted EBITDA increased by 55% compared to Q3'23. Catalent's pending transaction with Novo Holdings is expected to close by the end of 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Catalent (CTLT)?
What is the market cap of Catalent (CTLT)?
